Medicamen Biotech Ltd

AI
Medicamen Biotec Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents
AI

Medicamen Biotech Ltd

₹ 270 4.18%
04 Sep - close price
medicamen.com BSE: 531146 NSE: MEDICAMEQ
About

Incorporated in 1993, Medicamen Biotech Ltd is a research-led pharmaceutical company involved in developing, manufacturing, and marketing generic finished dosage formulations, and Oncology Formulations[1]

Key Points

Business Overview:[1][2][3]
MBL, a subsidiary of Shivalik Rasayan Ltd with 41.6% ownership, is an integrated Pharmaceutical and Life Sciences Solution Provider. They manufacture pharmaceutical formulations, primarily focusing on oncology therapeutics and generics, distributed through wholesale drug distributors and sold to institutional segments such as government and semi-government institutions, and hospitals. Their formulations cover beta-lactam, non-beta-lactam, and cephalosporin drugs for overseas and domestic markets.

Website BSE NSE
  • Market Cap ₹ 367 Cr.
  • Current Price ₹ 270
  • High / Low ₹ 454 / 210
  • Stock P/E 33.8
  • Book Value ₹ 203
  • Dividend Yield 0.37 %
  • ROCE 5.43 %
  • ROE 3.95 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company is expected to give good quarter

Cons

  • The company has delivered a poor sales growth of 11.9% over past five years.
  • Company has a low return on equity of 4.23% over last 3 years.
  • Dividend payout has been low at 14.5% of profits over last 3 years
  • Company has high debtors of 151 days.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
41.94 43.54 46.50 47.32 43.05 44.74 45.14 29.61 43.04 47.17 46.91 60.65 47.90
34.99 38.89 41.60 41.57 39.60 39.43 38.43 31.22 38.43 42.01 42.53 55.22 43.57
Operating Profit 6.95 4.65 4.90 5.75 3.45 5.31 6.71 -1.61 4.61 5.16 4.38 5.43 4.33
OPM % 16.57% 10.68% 10.54% 12.15% 8.01% 11.87% 14.86% -5.44% 10.71% 10.94% 9.34% 8.95% 9.04%
0.38 0.55 0.83 0.57 0.59 0.29 0.14 5.23 0.47 0.37 0.53 1.74 0.86
Interest 0.96 0.91 0.65 1.89 0.71 1.04 0.76 0.65 1.15 0.99 0.97 0.38 0.83
Depreciation 1.69 1.82 1.80 1.77 1.77 2.61 2.21 0.48 1.80 1.86 1.83 1.73 1.79
Profit before tax 4.68 2.47 3.28 2.66 1.56 1.95 3.88 2.49 2.13 2.68 2.11 5.06 2.57
Tax % 15.81% 39.68% 38.11% 22.93% 48.72% 53.85% 24.74% 25.30% 24.88% 21.27% 22.27% 12.06% 28.40%
3.95 1.47 2.03 2.04 0.80 0.91 2.92 1.87 1.60 2.12 1.64 4.45 1.85
EPS in Rs 3.30 1.19 1.90 1.68 1.06 1.15 2.73 1.90 1.59 1.97 1.61 2.85 1.56
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
123 125 113 115 141 179 163 198 203
105 106 93 91 117 156 148 178 183
Operating Profit 17 20 20 24 24 24 14 20 19
OPM % 14% 16% 17% 21% 17% 13% 9% 10% 10%
4 2 1 2 2 2 6 3 4
Interest 1 1 2 2 3 6 4 4 3
Depreciation 2 2 3 6 6 7 7 7 7
Profit before tax 18 18 16 18 17 13 10 12 12
Tax % 31% 26% 26% 18% 14% 27% 34% 18%
12 13 12 15 15 9 7 10 10
EPS in Rs 10.28 10.88 9.93 12.20 11.73 8.60 5.59 7.11 7.99
Dividend Payout % 10% 5% 10% 8% 9% 12% 18% 14%
Compounded Sales Growth
10 Years: %
5 Years: 12%
3 Years: 12%
TTM: 25%
Compounded Profit Growth
10 Years: %
5 Years: -4%
3 Years: -13%
TTM: 14%
Stock Price CAGR
10 Years: 4%
5 Years: -16%
3 Years: -27%
1 Year: -23%
Return on Equity
10 Years: %
5 Years: 6%
3 Years: 4%
Last Year: 4%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 12 12 12 12 13 13 13 14
Reserves 75 109 121 134 181 194 200 262
12 11 19 26 26 31 34 48
38 49 42 53 59 56 50 49
Total Liabilities 137 181 194 226 279 295 297 372
24 34 90 92 93 92 87 85
CWIP 15 40 0 0 0 0 0 0
Investments 0 0 0 0 0 0 0 0
97 107 104 133 186 203 210 287
Total Assets 137 181 194 226 279 295 297 372

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
4 13 13 4 -6 -7 -8 -33
-15 -37 -18 -8 -6 -6 -1 -3
-4 19 6 4 29 6 -1 64
Net Cash Flow -14 -5 1 -0 17 -6 -11 28
Free Cash Flow -11 -25 -5 -4 -13 -13 -10 -38
CFO/OP 48% 88% 88% 30% -13% -16% -47% -159%

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 129 145 170 200 169 112 155 151
Inventory Days 67 78 27 188 228 234 268 251
Days Payable 134 173 169 302 241 154 184 144
Cash Conversion Cycle 62 51 28 86 156 193 239 259
Working Capital Days 116 130 126 147 156 123 186 193
ROCE % 16% 13% 12% 10% 8% 6% 5%

Insights

In beta
Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Permanent Employees
count ・Standalone data

Log in to view insights

Please log in to see hidden values.

Login
Number of Countries Served
count ・Standalone data
Export Revenue Share
% ・Standalone data
Domestic Marketing and Sales Team
count
Africa Share of Revenue
% ・Standalone data
Products Registered Globally
count ・Standalone data
Products Under Registration and Filing
count ・Standalone data
R&D Team Size
count ・Standalone data

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
43.21% 43.21% 43.21% 42.99% 42.99% 42.99% 43.16% 40.46% 40.46% 40.46% 40.46% 40.46%
0.22% 0.22% 0.12% 0.06% 0.06% 0.06% 0.12% 0.00% 0.05% 0.02% 0.10% 0.07%
0.20% 0.67% 0.99% 1.17% 1.17% 0.87% 0.69% 0.64% 0.59% 0.44% 0.00% 0.40%
0.00% 0.00% 0.00% 0.00% 0.00% 0.06% 0.06% 0.05% 0.05% 0.05% 0.05% 0.05%
56.38% 55.90% 55.69% 55.78% 55.79% 56.04% 55.99% 58.83% 58.84% 59.02% 59.39% 59.01%
No. of Shareholders 9,41910,25210,63910,65210,79210,57610,43510,80811,17710,96710,80611,047

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls

  • Nov 2024
    Transcript
    AI Summary
    PPT
  • Dec 2021
    Transcript
    AI Summary
    PPT
  • Nov 2020
    Transcript
    AI Summary
    PPT
  • Aug 2020
    Transcript
    AI Summary
    PPT
  • Jun 2020
    Transcript
    AI Summary
    PPT